JP6978424B2 - ブロモドメイン阻害剤 - Google Patents
ブロモドメイン阻害剤 Download PDFInfo
- Publication number
- JP6978424B2 JP6978424B2 JP2018545668A JP2018545668A JP6978424B2 JP 6978424 B2 JP6978424 B2 JP 6978424B2 JP 2018545668 A JP2018545668 A JP 2018545668A JP 2018545668 A JP2018545668 A JP 2018545668A JP 6978424 B2 JP6978424 B2 JP 6978424B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridin
- pyrrolo
- oxo
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC*C(*=C(C(*)=C)C(*)=O)=C(*)N Chemical compound CCC*C(*=C(C(*)=C)C(*)=O)=C(*)N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021183089A JP2022024026A (ja) | 2016-04-15 | 2021-11-10 | ブロモドメイン阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016079362 | 2016-04-15 | ||
| CNPCT/CN2016/079362 | 2016-04-15 | ||
| PCT/CN2017/080511 WO2017177955A1 (en) | 2016-04-15 | 2017-04-14 | Bromodomain inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183089A Division JP2022024026A (ja) | 2016-04-15 | 2021-11-10 | ブロモドメイン阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511482A JP2019511482A (ja) | 2019-04-25 |
| JP2019511482A5 JP2019511482A5 (enExample) | 2020-03-19 |
| JP6978424B2 true JP6978424B2 (ja) | 2021-12-08 |
Family
ID=60042835
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545668A Expired - Fee Related JP6978424B2 (ja) | 2016-04-15 | 2017-04-14 | ブロモドメイン阻害剤 |
| JP2021183089A Ceased JP2022024026A (ja) | 2016-04-15 | 2021-11-10 | ブロモドメイン阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183089A Ceased JP2022024026A (ja) | 2016-04-15 | 2021-11-10 | ブロモドメイン阻害剤 |
Country Status (39)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2793239T3 (es) * | 2016-04-15 | 2020-11-13 | Abbvie Inc | Inhibidores del bromodominio |
| WO2018068283A1 (en) * | 2016-10-14 | 2018-04-19 | Abbvie Inc. | Bromodomain inhibitors |
| EP3612181A4 (en) | 2017-04-21 | 2021-01-06 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| EP3828183A4 (en) * | 2018-07-25 | 2022-03-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF |
| CN110776508B (zh) * | 2018-07-27 | 2021-07-16 | 海创药业股份有限公司 | 一种brd4抑制剂及其制备方法和用途 |
| WO2020063976A1 (zh) * | 2018-09-29 | 2020-04-02 | 如东凌达生物医药科技有限公司 | 一类稠杂环联芳基苄醇类化合物、制备方法和用途 |
| WO2020092638A1 (en) | 2018-10-30 | 2020-05-07 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
| BR112021018372A2 (pt) * | 2019-03-17 | 2021-11-23 | Shanghai Ringene Biopharma Co Ltd | Composto acilaminopirrolo-piridona, método para preparar o referido composto, composição farmacêutica e uso do mesmo |
| GB201905721D0 (en) * | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2020232214A1 (en) * | 2019-05-14 | 2020-11-19 | Abbvie Inc. | Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor |
| WO2021003310A1 (en) | 2019-07-02 | 2021-01-07 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
| PH12022550015A1 (en) * | 2019-07-30 | 2022-11-21 | Xrad Therapeutics Inc | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| CN115667254A (zh) * | 2020-05-21 | 2023-01-31 | 贝达药业股份有限公司 | 作为溴结构域蛋白质抑制剂的化合物和组合物 |
| GB202016977D0 (en) | 2020-10-26 | 2020-12-09 | In4Derm Ltd | Compounds |
| JP2023538405A (ja) * | 2020-12-01 | 2023-09-07 | 成都苑▲東▼生物制▲薬▼股▲ふん▼有限公司 | 新規ｎ－複素環ｂｅｔブロモドメイン阻害剤、その調製方法及び医薬応用 |
| CN117241805A (zh) * | 2021-01-08 | 2023-12-15 | 设计治疗公司 | 用于治疗弗里德希氏共济失调的方法和化合物 |
| CN115232131A (zh) * | 2021-04-23 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| CN115551861B (zh) * | 2021-04-30 | 2024-05-28 | 成都硕德药业有限公司 | 一种新型brd4溴结构域protac蛋白降解剂、其制备方法及医药用途 |
| IL309651A (en) | 2021-06-29 | 2024-02-01 | Tay Therapeutics Ltd | History Pyrolopyridone is useful in the treatment of cancer |
| CN115611890B (zh) * | 2021-07-15 | 2024-05-31 | 成都硕德药业有限公司 | 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途 |
| CN121399098A (zh) | 2023-06-30 | 2026-01-23 | 赛诺菲 | 取代的环状化合物以及治疗苯丙酮尿症和其他氨基酸尿症的方法 |
Family Cites Families (174)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATA210876A (de) | 1975-03-25 | 1979-01-15 | Byk Gulden Lomberg Chem Fab | Verfahren zur herstellung von neuen nidrofuryl- pyrazolderivaten |
| US4004012A (en) | 1975-10-14 | 1977-01-18 | Sterling Drug Inc. | 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones |
| US4072746A (en) | 1975-10-14 | 1978-02-07 | Sterling Drug Inc. | 3-Amino-5-(pyridinyl)-2(1H)-pyridinones |
| DE2845456A1 (de) | 1978-10-19 | 1980-08-14 | Merck Patent Gmbh | 6-arylpyridazin-3-one und verfahren zu ihrer herstellung |
| US4298609A (en) | 1979-08-30 | 1981-11-03 | Sterling Drug Inc. | 4,5-Dihydro-6-(4-pyridinyl)-3-pyridazinol and salts, their preparation and use as blood pressure lowering agents |
| FR2478640A1 (fr) | 1980-03-24 | 1981-09-25 | Sanofi Sa | Nouvelles thieno (2,3-d) pyridazinones-4 et thieno (2,3-d) pyridazinones-7, leur procede de preparation et leur therapeutique |
| US4486431A (en) | 1981-01-14 | 1984-12-04 | Sterling Drug Inc. | Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones |
| US4338446A (en) | 1980-04-28 | 1982-07-06 | Sterling Drug Inc. | Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates |
| US4337253A (en) | 1980-04-28 | 1982-06-29 | Sterling Drug Inc. | 4,5-Dihydro-2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone and its use as a cardiotonic |
| US4346221A (en) | 1980-04-28 | 1982-08-24 | Sterling Drug Inc. | Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones |
| US4305943A (en) | 1980-04-28 | 1981-12-15 | Sterling Drug Inc. | 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics |
| US4304776A (en) | 1980-04-28 | 1981-12-08 | Sterling Drug Inc. | 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics |
| US4559352A (en) | 1981-03-30 | 1985-12-17 | Sterling Drug Inc. | 1,2-Dihydro-2-oxo-5-(hydroxy-and/or amino-phenyl)-nicotinonitriles and cardiotonic use thereof |
| US4404203A (en) | 1981-05-14 | 1983-09-13 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| US4515797A (en) | 1981-09-08 | 1985-05-07 | Sterling Drug Inc. | 3-Amino-5-(hydroxy- and/or aminophenyl)-6-(lower-alkyl)-2(1H)-pyridinones and cardiotonic use thereof |
| US4465686A (en) | 1981-09-08 | 1984-08-14 | Sterling Drug Inc. | 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation |
| US4353905A (en) | 1981-09-17 | 1982-10-12 | Warner-Lambert Company | Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones |
| US4599423A (en) | 1982-04-26 | 1986-07-08 | Sterling Drug Inc. | Preparation of 5-(hydroxy- and/or aminophenyl-6-lower-alkyl)-2(1H)-pyridinones |
| US4734415A (en) | 1982-08-13 | 1988-03-29 | Warner-Lambert Company | Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones |
| DE3241102A1 (de) | 1982-11-06 | 1984-05-10 | A. Nattermann & Cie GmbH, 5000 Köln | Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung |
| DE3321012A1 (de) | 1983-06-10 | 1984-12-13 | A. Nattermann & Cie GmbH, 5000 Köln | Substituierte 4,5-dihydro-6-(thien-2-yl)-3(2h)-pyridazinone und 6-(thien-2-yl)-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung |
| US4666902A (en) | 1983-06-20 | 1987-05-19 | Cassella Aktiengesellschaft | Tetrahydropyridazinone derivatives, processes for their preparation and their use |
| GB8323553D0 (en) | 1983-09-02 | 1983-10-05 | Smith Kline French Lab | Pharmaceutical compositions |
| US4816454A (en) | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
| US5112625A (en) | 1989-02-15 | 1992-05-12 | Wm. Wrigley Jr. Company | Aqueous zein coated sweeteners and other ingredients for chewing gum |
| US5217735A (en) | 1986-10-22 | 1993-06-08 | Wm. Wrigley Jr. Company | Method of making chewing gum with delayed release ingredients |
| US4863745A (en) | 1986-10-22 | 1989-09-05 | Wm. Wrigley Jr. Company | Chewing gum containing zein coated high-potency sweetener and method |
| US5192563A (en) | 1986-10-22 | 1993-03-09 | Wm. Wrigley, Jr. Company | Strongly mint-flavored chewing gums with reduced bitterness and harshness |
| US5221543A (en) | 1986-10-22 | 1993-06-22 | Firma Wilhelm Fette Gmbh | Method of making a fast release stabilized aspartame ingredient for chewing gum |
| US4908371A (en) | 1987-11-10 | 1990-03-13 | Ciba-Geigy Corporation | Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload |
| US4919941A (en) | 1987-12-18 | 1990-04-24 | Wm. Wrigley Jr. Company | Chewing gum containing delayed release protein sweetener and method |
| DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| AU7238191A (en) | 1990-02-19 | 1991-09-03 | Chugai Seiyaku Kabushiki Kaisha | Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom |
| DE4023369A1 (de) | 1990-07-23 | 1992-01-30 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| ES2131506T3 (es) | 1990-09-21 | 1999-08-01 | Rohm & Haas | Dihidropiridacinonas y piridacinonas como fungicidas. |
| EP0503079A4 (en) | 1990-10-02 | 1992-10-28 | Kaken Pharmaceutical Co., Ltd. | Pyridazinone-substituted ethynylphenyl derivative and remedy for circulatory organ disease containing the same as active ingredient |
| DE4127404A1 (de) | 1991-08-19 | 1993-02-25 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| CN1038249C (zh) | 1991-08-28 | 1998-05-06 | 罗姆和哈斯公司 | 含有二氢哒嗪酮及其相关化合物的杀菌组合物 |
| US5716954A (en) | 1991-10-09 | 1998-02-10 | Syntex U.S.A. Inc. | Benzopyridazinone and pyridopyridazinone compounds |
| NZ244660A (en) | 1991-10-09 | 1995-05-26 | Syntex Inc | Pyridopyridazine derivatives and medicaments |
| DE4237656A1 (de) | 1992-06-13 | 1993-12-16 | Merck Patent Gmbh | Benzimidazolderivate |
| EP0666851A4 (en) | 1992-11-02 | 1995-08-30 | Merck & Co. Inc. | Substituted phthalazinones as nerotensin antagonists. |
| US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| EP0634404A1 (en) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazin derivatives and their use as pesticides |
| GB9314412D0 (en) | 1993-07-13 | 1993-08-25 | Rhone Poulenc Agriculture | New compositions of matter |
| TW263498B (enExample) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| JP3247540B2 (ja) | 1994-05-12 | 2002-01-15 | 株式会社日立製作所 | パケット化通信装置および切替え装置 |
| US5466697A (en) | 1994-07-13 | 1995-11-14 | Syntex (U.S.A.) Inc. | 8-phenyl-1,6-naphthyridin-5-ones |
| AU691673B2 (en) | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| JPH08337583A (ja) | 1995-04-13 | 1996-12-24 | Takeda Chem Ind Ltd | 複素環化合物およびその製造法 |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| JPH11508267A (ja) | 1995-06-26 | 1999-07-21 | 藤沢薬品工業株式会社 | ピラゾール化合物および医薬組成物 |
| IL118631A (en) | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| AU723064B2 (en) | 1995-08-25 | 2000-08-17 | Dow Agrosciences Llc | Compositions having synergistic fungitoxic effects |
| KR100338144B1 (ko) | 1996-09-13 | 2002-05-24 | 가마쿠라 아키오 | 티에노트리아졸로디아제핀 화합물 및 그의 약제학적 용도 |
| US5855654A (en) | 1997-01-30 | 1999-01-05 | Rohm And Haas Company | Pyridazinones as marine antifouling agents |
| PT984961E (pt) | 1997-04-01 | 2001-11-30 | Astrazeneca Ab | Novos derivados de piridina e composicoes farmaceuticas que os contem |
| US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
| US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| AU738595B2 (en) | 1997-11-19 | 2001-09-20 | Kowa Co., Ltd. | Novel pyridazine derivatives and medicines containing the same as effective ingredients |
| SK8402000A3 (en) | 1997-12-05 | 2001-03-12 | Astrazeneca Uk Ltd | Novel compounds |
| EP0934933A1 (en) | 1998-02-06 | 1999-08-11 | Byk Gulden Lomberg Chemische Fabrik GmbH | Phthalazinones |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| JP3910365B2 (ja) | 1998-07-16 | 2007-04-25 | 塩野義製薬株式会社 | 抗腫瘍活性を有するピリミジン誘導体 |
| US6271380B1 (en) | 1998-12-30 | 2001-08-07 | Dupont Pharmaceuticals Company | 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands |
| CN1297916A (zh) | 1999-11-26 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人含溴基结构域的蛋白95和编码这种多肽的多核苷酸 |
| DE10010423A1 (de) | 2000-03-03 | 2001-09-06 | Bayer Ag | Substituierte 2,5-Dimethyldihydropyridazinone und ihre Verwendung |
| CN1315397A (zh) | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人溴基结构域10和编码这种多肽的多核苷酸 |
| AU5696800A (en) | 2000-07-04 | 2002-01-14 | Robert John Eyre | Harvesting machine |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2003313169A (ja) | 2002-04-19 | 2003-11-06 | Otsuka Chemical Holdings Co Ltd | ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤 |
| ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| WO2004014892A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| WO2004014384A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| CN1812981A (zh) | 2003-06-27 | 2006-08-02 | 万有制药株式会社 | 杂芳氧基含氮饱和杂环衍生物 |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| DE602004025258D1 (de) | 2003-08-06 | 2010-03-11 | Vertex Pharma | Aminotriazol-verbindungen als proteinkinase-hemmer |
| TWI339206B (en) * | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| CN1870896A (zh) | 2003-10-20 | 2006-11-29 | 默克公司 | 用作hiv整合酶抑制剂的羟基吡啶并吡咯并吡嗪二酮化合物 |
| SG115845A1 (en) | 2004-03-31 | 2005-10-28 | Univ Singapore | Modulation of trip-br function and method of treating proliferative disorders |
| KR100958829B1 (ko) * | 2004-09-03 | 2010-05-25 | 주식회사유한양행 | 피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법 |
| GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
| WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
| US20080090827A1 (en) | 2004-11-30 | 2008-04-17 | Artesian Therapeutics, Inc. | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure |
| JPWO2006059778A1 (ja) | 2004-12-01 | 2008-06-05 | 萬有製薬株式会社 | 置換ピリドン誘導体 |
| AU2006223236A1 (en) | 2005-03-14 | 2006-09-21 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| US20060276496A1 (en) | 2005-03-17 | 2006-12-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-Cytokine Heterocyclic Compounds |
| JPWO2006112331A1 (ja) | 2005-04-13 | 2008-12-11 | 大日本住友製薬株式会社 | 新規縮合ピロール誘導体 |
| US8044042B2 (en) | 2005-05-30 | 2011-10-25 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and medicinal use thereof |
| WO2007008144A1 (en) | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| WO2007008145A1 (en) | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| ES2380236T3 (es) | 2005-10-28 | 2012-05-09 | Takeda Pharmaceutical Company Limited | Compuesto de amida heterocíclica y uso del mismo |
| EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US20070142414A1 (en) | 2005-12-16 | 2007-06-21 | Pharmacia Italia S.P.A. | N-substituted pyrrolopyridinones active as kinase inhibitors |
| US8247414B2 (en) | 2006-07-25 | 2012-08-21 | Cephalon, Inc. | Pyridizinone derivatives and the use thereof as H3 inhibitors |
| WO2008024978A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| SG178786A1 (en) | 2006-11-13 | 2012-03-29 | Lilly Co Eli | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| EP2094702B1 (en) | 2006-12-14 | 2015-09-02 | Gilead Sciences, Inc. | Viral inhibitors |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| WO2008148034A1 (en) | 2007-05-25 | 2008-12-04 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| JP5470557B2 (ja) | 2007-07-26 | 2014-04-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成 |
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| ES2499017T3 (es) | 2007-10-23 | 2014-09-26 | F. Hoffmann-La Roche Ag | Nuevos inhibidores de quinasa |
| WO2009054790A1 (en) | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8476260B2 (en) | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| KR20110002492A (ko) | 2008-05-01 | 2011-01-07 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| US8242111B2 (en) | 2008-05-01 | 2012-08-14 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| CA2723034A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| WO2010127237A2 (en) | 2009-04-30 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| KR20110050459A (ko) | 2008-07-25 | 2011-05-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| JP2011530596A (ja) | 2008-08-11 | 2011-12-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用 |
| HRP20120992T1 (hr) | 2008-11-20 | 2012-12-31 | Merck Sharp & Dohme Corp. | Aril metil benzokinazolinon kao pozitivni alosterni modulatori receptora m1 |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US9102677B2 (en) | 2009-11-05 | 2015-08-11 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| MX2012005295A (es) | 2009-11-05 | 2012-06-19 | Glaxosmithkline Llc | Inhibidor de bromodominio de benzodiazepina. |
| ES2539964T3 (es) | 2009-11-05 | 2015-07-07 | Glaxosmithkline Llc | Procedimiento novedoso |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US20130061612A1 (en) | 2009-11-11 | 2013-03-14 | E.I. Du Pont De Nemours And Company | Refrigerant storage in secondary loop refrigeration systems |
| WO2011133722A2 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Anti-viral compounds |
| MX362384B (es) | 2010-05-14 | 2019-01-15 | Dana Farber Cancer Inst Inc | Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| US9085582B2 (en) | 2010-06-22 | 2015-07-21 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| JP2015505087A (ja) | 2011-12-07 | 2015-02-16 | アフェクティヴァ, インコーポレイテッドAffectiva, Inc. | 広告効果の感情に基づく評価 |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20130188311A1 (en) | 2012-01-23 | 2013-07-25 | International Business Machines Corporation | Cooling and noise-reduction apparatus |
| CN104334526A (zh) | 2012-04-20 | 2015-02-04 | 艾伯维公司 | 异吲哚酮衍生物 |
| RU2632915C2 (ru) | 2012-06-12 | 2017-10-11 | Эббви Инк. | Производные пиридинона и пиридазинона |
| WO2013188311A1 (en) | 2012-06-15 | 2013-12-19 | Soft Machines, Inc. | A load store buffer agnostic to threads implementing forwarding from different threads based on store seniority |
| US20140094456A1 (en) | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014125408A2 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
| WO2014164771A1 (en) | 2013-03-11 | 2014-10-09 | Abbvie Inc. | Bromodomain inhibitors |
| BR112015022674A2 (pt) | 2013-03-11 | 2017-07-18 | Abbvie Inc | inibidores de bromodomínio |
| CA2905426A1 (en) | 2013-03-12 | 2014-10-09 | Abbvie Inc. | Pyrrole amide inhibitors |
| EP2970276A1 (en) | 2013-03-12 | 2016-01-20 | AbbVie Inc. | Dihydro-pyrrolopyridinone bromodomain inhibitors |
| US10035800B2 (en) | 2013-03-12 | 2018-07-31 | Abbvie Inc. | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors |
| EP3013828A4 (en) | 2013-06-28 | 2016-11-23 | Abbvie Inc | BROMDOMÄNENINHIBITOREN |
| AR096758A1 (es) | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
| CN103387576A (zh) * | 2013-08-09 | 2013-11-13 | 中国药科大学 | 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
| HRP20221389T1 (hr) * | 2013-10-18 | 2023-01-06 | Celgene Quanticel Research, Inc. | Inhibitori bromodomena |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
| US20150148372A1 (en) | 2013-11-26 | 2015-05-28 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| AU2014363989A1 (en) | 2013-12-09 | 2016-06-16 | Abbvie Inc. | Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors |
| EP3080132A4 (en) | 2013-12-10 | 2017-08-02 | AbbVie Inc. | Bromodomain inhibitors |
| WO2015164480A1 (en) | 2014-04-23 | 2015-10-29 | Incyte Corporation | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| ES2815683T3 (es) | 2015-05-11 | 2021-03-30 | Bristol Myers Squibb Co | Compuestos tricíclicos como agentes antineoplásicos |
| EP3307740B1 (en) | 2015-05-12 | 2019-12-18 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
| JP6606444B2 (ja) | 2016-03-10 | 2019-11-13 | 株式会社Ｓｕｂａｒｕ | 車両用制御装置 |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| ES2793239T3 (es) * | 2016-04-15 | 2020-11-13 | Abbvie Inc | Inhibidores del bromodominio |
| RU2769448C2 (ru) | 2016-04-15 | 2022-03-31 | Байер Энимэл Хельс ГмбХ | Новые пиразолпиримидиновые производные |
| KR102571679B1 (ko) | 2016-04-15 | 2023-08-29 | 에피자임, 인코포레이티드 | Ehmt1 및 ehmt2 저해제로서의 아민-치환된 아릴 또는 헤테로아릴 화합물 |
| AU2017251378B2 (en) | 2016-04-15 | 2021-08-05 | Syngenta Crop Protection Ag | Herbicidal pyridazinone compounds |
| US11298354B2 (en) | 2016-06-09 | 2022-04-12 | Dana-Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors |
| WO2017216772A2 (en) | 2016-06-16 | 2017-12-21 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
| WO2017223268A1 (en) | 2016-06-22 | 2017-12-28 | Yale University | COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi) |
| WO2018068283A1 (en) | 2016-10-14 | 2018-04-19 | Abbvie Inc. | Bromodomain inhibitors |
| EP3800182A1 (en) | 2016-10-14 | 2021-04-07 | AbbVie Inc. | Pyridin-2(1h)-one derivatives as bromodomain inhibitors |
| WO2018095933A1 (en) | 2016-11-22 | 2018-05-31 | Université D'aix-Marseille (Amu) | Method of prognosticating, or for determining the efficiency of a compound for treating cancer |
| WO2018130174A1 (zh) | 2017-01-11 | 2018-07-19 | 江苏豪森药业集团有限公司 | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
| US20210130346A1 (en) | 2017-04-14 | 2021-05-06 | Abbvie Inc. | Bromodomain Inhibitors |
| WO2018223909A1 (zh) | 2017-06-05 | 2018-12-13 | 成都海创药业有限公司 | 一种嵌合分子及其制备和应用 |
| CN108690020A (zh) | 2018-07-04 | 2018-10-23 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
-
2017
- 2017-04-14 ES ES17781931T patent/ES2793239T3/es active Active
- 2017-04-14 PT PT177819315T patent/PT3442972T/pt unknown
- 2017-04-14 PL PL17781931T patent/PL3442972T3/pl unknown
- 2017-04-14 MX MX2018012541A patent/MX379459B/es unknown
- 2017-04-14 DK DK17781931.5T patent/DK3442972T3/da active
- 2017-04-14 MA MA44674A patent/MA44674B1/fr unknown
- 2017-04-14 RU RU2018140061A patent/RU2741808C2/ru active
- 2017-04-14 MA MA052814A patent/MA52814A/fr unknown
- 2017-04-14 MD MDE20190228T patent/MD3442972T2/ro unknown
- 2017-04-14 TW TW109127958A patent/TWI764237B/zh active
- 2017-04-14 BR BR112018071216A patent/BR112018071216A2/pt active Search and Examination
- 2017-04-14 LT LTEP17781931.5T patent/LT3442972T/lt unknown
- 2017-04-14 PE PE2018001988A patent/PE20190472A1/es unknown
- 2017-04-14 WO PCT/CN2017/080511 patent/WO2017177955A1/en not_active Ceased
- 2017-04-14 HU HUE17781931A patent/HUE050217T2/hu unknown
- 2017-04-14 CA CA3018802A patent/CA3018802A1/en active Pending
- 2017-04-14 TW TW106112643A patent/TWI704147B/zh not_active IP Right Cessation
- 2017-04-14 CN CN201780023689.1A patent/CN109071534B/zh active Active
- 2017-04-14 EP EP17781931.5A patent/EP3442972B1/en active Active
- 2017-04-14 SG SG11201808003RA patent/SG11201808003RA/en unknown
- 2017-04-14 SI SI201730258T patent/SI3442972T1/sl unknown
- 2017-04-14 KR KR1020187030341A patent/KR102250415B1/ko active Active
- 2017-04-14 TW TW111113671A patent/TW202304907A/zh unknown
- 2017-04-14 US US16/093,483 patent/US10633379B2/en active Active
- 2017-04-14 EP EP20160781.9A patent/EP3693369A3/en not_active Withdrawn
- 2017-04-14 CR CR20180541A patent/CR20180541A/es unknown
- 2017-04-14 UA UAA201811188A patent/UA124764C2/uk unknown
- 2017-04-14 RS RS20200588A patent/RS60302B1/sr unknown
- 2017-04-14 MY MYPI2018703563A patent/MY190795A/en unknown
- 2017-04-14 JP JP2018545668A patent/JP6978424B2/ja not_active Expired - Fee Related
- 2017-04-14 HR HRP20200728TT patent/HRP20200728T1/hr unknown
- 2017-04-14 SM SM20200312T patent/SMT202000312T1/it unknown
- 2017-04-14 AU AU2017251537A patent/AU2017251537B2/en not_active Ceased
- 2017-04-17 AR ARP170100968A patent/AR108207A1/es not_active Application Discontinuation
- 2017-04-18 UY UY0001037205A patent/UY37205A/es not_active Application Discontinuation
-
2018
- 2018-09-04 IL IL261586A patent/IL261586B/en active IP Right Grant
- 2018-09-07 PH PH12018501920A patent/PH12018501920B1/en unknown
- 2018-10-12 CL CL2018002924A patent/CL2018002924A1/es unknown
- 2018-10-12 DO DO2018000227A patent/DOP2018000227A/es unknown
- 2018-10-16 CO CONC2018/0011064A patent/CO2018011064A2/es unknown
- 2018-11-08 EC ECSENADI201883519A patent/ECSP18083519A/es unknown
-
2020
- 2020-04-27 US US16/858,930 patent/US20200255426A1/en not_active Abandoned
- 2020-05-22 CY CY20201100494T patent/CY1123025T1/el unknown
- 2020-12-14 ME MEP-2020-128A patent/ME03759B/me unknown
-
2021
- 2021-01-08 AU AU2021200101A patent/AU2021200101A1/en not_active Abandoned
- 2021-02-24 US US17/183,832 patent/US20220017511A1/en not_active Abandoned
- 2021-11-10 JP JP2021183089A patent/JP2022024026A/ja not_active Ceased
-
2023
- 2023-11-21 US US18/516,230 patent/US20240360124A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6978424B2 (ja) | ブロモドメイン阻害剤 | |
| JP6371430B2 (ja) | ブロモドメイン阻害薬 | |
| JP6423425B2 (ja) | 結晶性ブロモドメインインヒビター | |
| CN105164113B (zh) | 吡咯酰胺抑制剂 | |
| JP2016539970A (ja) | ブロモドメイン阻害薬として有用なジヒドロピリジノンおよびジヒドロピリダジノン誘導体 | |
| JP2015514780A (ja) | イソインドロン誘導体 | |
| US20140275026A1 (en) | Dihydro-pyrrolopyridinone inhibitors | |
| JP2021102619A (ja) | ブロモドメイン阻害剤 | |
| JP2021102617A (ja) | ブロモドメイン阻害剤 | |
| HK40002495B (zh) | 布罗莫结构域抑制剂 | |
| HK40002495A (en) | Bromodomain inhibitors | |
| NZ787301A (en) | Bromodomain inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200207 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210507 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211012 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211111 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6978424 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |